Product Description
TP-38 (Teva Pharmaceuticals, formerly IVAX Inc., Miami, FL, USA) is a recombinant chimeric protein composed of transforming growth factor _ (TGF-_), an epidermal growth factor receptor (EGFR) ligand, and the genetically engineered form of PE described above (see IL4-PE). (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074673/)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IXR-202-22-188 | P2 |
Completed |
Glioblastoma |
2007-04-01 |
|
| IXR-102-22-188 | P2 |
Completed |
Glioblastoma |
2006-01-01 |